Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy

News summary

Novo Nordisk on Monday said it is rebranding its name to "Novo" and updating its corporate culture, as the company works to win back market share in the obesity drug space.